Modern molecular diagnostics demand high analytical sensitivity, reproducibility, and stability, particularly when detecting low-abundance nucleic acid targets. At Arni Medica, our molecular diagnostics strategy is grounded in deep scientific expertise in nanotechnology and nucleic acid engineering. As a contributing author of the Springer Nature book chapter Nucleic Acid-Based Micellar Therapy for the Treatment of Different Diseases, Dr. Madhukiran Parvathaneni has contributed to advancing the understanding of micellar and nano-engineered systems and their translational relevance in molecular medicine.
The chapter details how self-assembled micellar structures, formed using amphiphilic polymers and lipids, can encapsulate nucleic acids, protect them from enzymatic degradation, and enable controlled biological interaction. Key parameters such as particle size control, surface chemistry, molecular stabilization, and release kinetics are highlighted as essential for reliable nucleic acid handling.
While originally explored in therapeutic contexts, these principles are directly applicable to Nucleic Acid Amplification Test (NAAT) workflows; where nucleic acid integrity, inhibitor management, and reaction kinetics determine assay performance.
In NAAT diagnostics, nano-engineered micellar systems provide advantages across critical workflow stages, including sample lysis, nucleic acid stabilization, amplification efficiency, and signal consistency. Understanding nano–bio interfaces supports improved low-copy-number detection, reduced amplification inhibition, and optimized signal-to-noise ratios, which are essential for rapid and point-of-care molecular diagnostics.
This expertise strengthens Arni Medica’s ability to develop and evaluate NAAT-based diagnostic assays that are robust, scalable, and clinically reliable.
Leveraging this foundation, Arni Medica is aligning its NAAT portfolio toward high-impact infectious disease panels:
Respiratory Infections: SARS-CoV-2, Influenza A/B, RSV (multiplex respiratory panels)
Tropical & Vector-Borne Diseases: Dengue (DENV 1-4), Chikungunya, Zika, Malaria
Sexually Transmitted Infections: HIV-1/2, HBV, HCV, Chlamydia trachomatis, Neisseria gonorrhoeae
Gastrointestinal Infections: Salmonella, Shigella, Campylobacter, Rotavirus, Norovirus
Hospital-Acquired & AMR Markers: MRSA, VRE, carbapenemase genes (NDM, KPC, OXA)
These NAAT panels are designed to complement Arni Medica’s rapid tests, FIA, and CLIA platforms, enabling a tiered diagnostics approach—from screening to confirmatory molecular testing.
By integrating nanotechnology-driven nucleic acid stabilization with NAAT assay design, Arni Medica bridges advanced molecular science with practical diagnostic deployment, supporting precision detection across infectious diseases, oncology, and genetic markers.
Nucleic Acid-Based Micellar Therapy for the Treatment of Different Diseases.
Springer Nature.
https://doi.org/10.1007/978-981-99-0361-0_8
